Outsourcing revenue cycle management became a rational response to rising labor costs, payer complexity, and the growing expense of building AI capabilities internally. Labor costs for specialized RCM talent rose 258% following the pandemic. The vendor market responded directly: major RCM vendors acquired AI capability through strategic transactions specifically to absorb the investment burden their clients could not justify carrying. For PE-backed specialty platforms operating on a defined hold period, transferring that burden to a vendor was a sound financial decision. Black Book's 2025 survey of over 1,300 hospitals confirmed the direction: 83% of large physician groups plan to expand or initiate third-party RCM partnerships within the next year.
The hidden risk is that most organizations outsource before establishing an independent baseline of how their revenue cycle actually performs. Once a vendor's reporting becomes the primary source of truth, AI can improve activity and throughput while obscuring whether financial outcomes are genuinely improving.
That governance problem, not the technology itself, is where the greatest financial and compliance risk now resides.
The Revenue Cycle the Vendor Inherited
Most PE-backed specialty platforms are built through acquisition. Speed creates value, but it also creates operational inconsistency. Charge capture processes vary by location. Coding practices reflect individual provider habits. Denial patterns stem from local workflows that predate the acquisition. RCM staff turnover runs between 30% and 40% annually. When key people leave, so does the institutional knowledge they carried.
Most organizations enter outsourced RCM relationships without independently answering four fundamental questions: What is our true net collection rate by payer? Which denial categories drive the greatest revenue loss? How does performance vary across locations? What does success look like for our specific payer mix?
Without an independently established baseline, the vendor's reporting framework becomes the organization's operational reality by default.
When AI Enters the Picture
Black Book surveys from early 2025 found AI and RPA capability requirements climbing from 91% to 93% of revenue cycle leaders in just two months, a signal of how quickly vendor expectations are hardening. The defensive logic is sound. Medical necessity denials increased 5% in 2024 while prior authorization requests for additional clinical information increased 5.4%. Providers who cannot match payer-side AI capability will continue losing ground on reimbursement they have already earned.
The question is what happens when AI deploys on top of operational inconsistency.
Adaptive AI models calibrate against your organization's historical claims data, denial patterns, and payer responses. When that history reflects inconsistent documentation or miscoded claims caused by operational problems rather than clinical reality, the model learns those patterns as correct and optimizes to reproduce them. AI-generated denial appeals carry a related risk: these tools draft correspondence against your clinical documentation, producing well-constructed arguments that are only as defensible as the records behind them.
Three risks emerge consistently.
The Attribution Problem. When results fail to improve, isolating the cause becomes genuinely difficult. Was the model configured correctly? Was the underlying data consistent enough to calibrate against? Did payer behavior shift during implementation? That ambiguity tends to protect the vendor while making accountability harder for the client.
The Data Quality Trap. AI systems process operational variability as if it represents a coherent model. The outputs appear precise. Precision should not be confused with accuracy. Without independent oversight, organizations cannot determine whether AI-driven recommendations reflect financial reality or mirror historical inconsistency at speed.
The Compliance Risk. In January 2026, affiliates of Kaiser Permanente paid $556 million to resolve False Claims Act allegations after an NLP-based tool generated physician queries to add unsubmitted diagnoses to patient records, often months after the original encounter. Internal compliance staff raised concerns the organization did not act on. In 2022, University of Colorado Health paid $23 million after an automated coding rule assigned the highest-level emergency department code regardless of patient severity. Their own coders flagged the problem. The rule was not adjusted.
The common thread was not defective technology. Both organizations deployed automated tools without maintaining the internal capacity to validate outcomes and intervene when signals indicated a problem. The DOJ has named AI-powered billing errors and practices by private equity-owned medical groups as explicit enforcement priorities. At a PE-backed platform where RCM is fully outsourced and internal leadership is thin, that oversight role belongs to no one.
Four Conditions for Vendor AI Accountability
Most mid-sized organizations lack the leverage to reshape large vendor contracts. Protection comes from organizational readiness, not contract language.
- Establish an Independent Baseline. Before signing or renewing any vendor agreement, measure net collection rate by payer, denial rate by category and location, days in A/R by payer class, prior authorization approval rates by specialty, and revenue per encounter against benchmark, independently of the vendor. Without this, improvement gets measured against a starting point the vendor defined.
- Define Expected Outcomes in Writing. Activity SLAs measure whether work occurred, not whether financial performance improved. A vendor can satisfy every activity SLA while net collection rate quietly erodes. Documenting what success looks like before performance discussions begin creates a record that matters when remediation becomes a negotiation.
- Build Internal Analytical Capacity. Access to data is rarely the problem. The challenge is having someone capable of asking the questions the dashboard was not designed to answer. Why did commercial denials improve while Medicare Advantage did not? Why did authorization approval rates rise without corresponding improvement in collections? That requires someone with enough operational depth to know what the numbers should mean and enough standing to demand answers.
- Assign Clear Executive Ownership. Someone must own the vendor relationship with sufficient authority and operational knowledge to challenge performance when necessary. Without clear ownership, underperformance gradually becomes the accepted baseline. Governance requires independent validation between quarterly business reviews, not just attendance at them.
The Question Before the Next QBR
Before your vendor's next quarterly business review, answer these questions without relying on vendor-provided reporting.
What is your actual net collection rate by payer and location, measured against the baseline that existed before this vendor relationship began? What percentage of recent denials fall into categories the vendor's AI was contracted to prevent? Who validated that the vendor's AI was configured for your payer mix, documentation standards, and patient population before it went live?
If answering those questions requires a call to your vendor, your organization may have outsourced more than revenue cycle operations. You may have outsourced visibility itself.
Melanie Tisman is a Revenue Cycle Management executive with 20 years of experience in ambulatory settings including oncology and infusion therapy, ophthalmology and optometry, genomics, and telehealth. She holds an MBA and dual HFMA certifications, CHFP and CPBI.